MedTrace Logo

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

NCT06820567 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2025-02-11

No results posted yet for this study

Summary

the effect of Dapagliflozin on erythropoiesis, iron metabolism and inflammatory markers in CKD with Type 2 DM-Compare between effect of placebo and dapagliflozin on erythropoiesis, iron metabolism and inflammation markers in CKD with Type 2 DM.

Conditions

  • Chronic Kidney Diseases
  • Diabetes Type 2

Interventions

DRUG

Dapagliflozin (DAPA)

patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients

DRUG

Placebo

type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Mai Mostafa, MD · professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2026-03-01
Completion
2027-05-01
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06820567 on ClinicalTrials.gov